ABSTRACT
Monovalent Omicron XBB.1.5 mRNA vaccines (BNT162b2 XBB.1.5 and mRNA- 1273.815) were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines in healthy volunteers. We analyzed repeated blood samples before and after vaccination for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.
Competing Interest Statement
K.Yakushijin has received research grants and honoraria from Chugai Pharmaceutical and Pfizer. T.M. is an employee of Maruho Co., Ltd. K.D. and H.S. are employees of Cellspect Co., Ltd. T.S. is an employee of KAICO Ltd. N.K. has received grants from Roche Pharmaceuticals. H.M. has received research grants and honoraria from Chugai Pharmaceutical. The other authors declare no potential conflicts of interest.
Funding Statement
This study was funded by Division of Medical Oncology/Haematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by Kobe University Hospital Ethics Committee (No. B2356701). The study was conducted in accordance with the principles of the Declaration of Helsinki. The participants provided written informed consent for this research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
